Kramer H J, Glänzer K, Freitag T, Schönfeld J, Sorger M, Schlebusch H, Düsing R, Krück F
Klin Wochenschr. 1985 Jan 2;63(1):32-6. doi: 10.1007/BF01537484.
An endogenous humoral factor which inhibits the sodium- and potassium-activated adenosine triphosphatase (Na-K-ATPase) enzyme in vitro has been incriminated recently of playing a pathogenetic role in experimental and human hypertension. The present study was therefore performed in six healthy volunteers to investigate the hemodynamic consequences of an inhibition of this enzyme by ouabain, a potent and specific inhibitor of Na-K-ATPase. In addition, the role of intracellular calcium as a potential mediator was studied indirectly by the administration of nifedipine, a potent calcium entry blocker with predominant vasodilator properties. Intravenous administration of 8.5 micrograms ouabain/kg body weight inhibited red blood cell (RBC) - Na-K-ATPase by 49% which was accompanied by a significant increase in RBC - ATP and a decrease in intracellular potassium concentrations. This enzyme inhibition resulted in a 24% increase in peripheral vascular resistance. The parallel decrease in cardiac output and heart rate, however, prevented a rise in arterial pressure. This increase in vascular resistance was completely abolished by pretreatment with nifedipine (10 mg orally). In the absence of an effect of nifedipine on Na-K-ATPase, its attenuation of the vasoconstrictor effect of ouabain suggests that the effects of ouabain on the vascular smooth muscle cell are mediated by intracellular calcium. These results demonstrate that inhibition of the Na-K-ATPase enzyme in vivo causes a marked peripheral vasoconstriction. They are also compatible with the concept that an endogenous inhibitor of Na-K-ATPase - in the presence of decreased baroreceptor reflex sensitivity due to blood volume expansion - may play a role in the pathogenesis of human arterial hypertension.
最近有研究表明,一种内源性体液因子在体外可抑制钠钾激活的三磷酸腺苷酶(Na-K-ATP酶),并在实验性高血压和人类高血压的发病机制中发挥作用。因此,本研究选取了6名健康志愿者,旨在探讨哇巴因(一种强效且特异性的Na-K-ATP酶抑制剂)对该酶的抑制作用所产生的血流动力学后果。此外,通过给予硝苯地平(一种具有主要血管舒张特性的强效钙通道阻滞剂)间接研究了细胞内钙作为潜在介导因子的作用。静脉注射8.5微克/千克体重的哇巴因可使红细胞(RBC)的Na-K-ATP酶活性降低49%,同时伴有红细胞ATP显著增加和细胞内钾浓度降低。这种酶抑制作用导致外周血管阻力增加24%。然而,心输出量和心率的相应降低阻止了动脉血压的升高。硝苯地平(口服10毫克)预处理可完全消除这种血管阻力的增加。在硝苯地平对Na-K-ATP酶无作用的情况下,其对哇巴因血管收缩作用的减弱表明,哇巴因对血管平滑肌细胞的作用是由细胞内钙介导的。这些结果表明,体内抑制Na-K-ATP酶会导致明显的外周血管收缩。这也与以下观点相符:在由于血容量增加导致压力感受器反射敏感性降低的情况下,Na-K-ATP酶的内源性抑制剂可能在人类动脉高血压的发病机制中起作用。